The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Importance of vitamin D for bisphosphonate therapy

    Several studies suggest that the response to bisphosphonates could in part be dependent on circulating blood levels of vitamin D.

    Researchers at Weill Cornell Medical College, in New York City, examined the association between blood levels of 25 hydroxy vitamin D [25(OH)D] and the response to bisphosphonate treatment.

    First, the details.

    • 210 postmenopausal women with low bone mineral density (BMD) treated for longer than 18 months with bisphosphonates participated in the study.
    • Average 25(OH)D levels were compared between responders and non-responders.
    • An analysis was performed to identify factors associated with non-response.

    And, the results.

    • Average duration of bisphosphonate treatment was 63 months.
    • Most patients were Caucasian (83%).
    • Patients were treated with alendronate (Fosamax), risedronate (Actonel), or zolendronate (Zometa, Zomera, Aclasta, Reclast).
    • 47% had a favorable response to bisphosphonates — prevent bone loss and the treat established osteoporosis.
    • Patients with an average 25(OH)D blood level of at least 33 ng/mL had a significant 4.5 fold greater odds of bisphosphonate response.
    • 25(OH)D levels were significantly associated with response to bisphosphonates – 1 ng/mL decrease in 25(OH)D was associated with about a 5% decrease in odds of responding — a significant difference.

    The bottom line?

    The authors concluded, “The current study is the first to identify a threshold level of 25(OH)D that defines improved outcome to bisphosphonate therapy such that patients with a mean 25(OH)D at least 33 ng/mL had a substantially greater likelihood of responding to bisphosphonates.

    Check you blood levels of vitamin D while taking bisphosphonates.

    10/18/11 20:27 JR

    Leave a Comment

    XHTML: Line-breaks are automatic. Available tags are <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>